MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Pfizer Inc. (Narrative) (Details)		1 Months Ended			12 Months Ended		37 Months Ended	44 Months Ended	97 Months Ended	104 Months Ended
	Oct. 27, 2025 USD ($)	Dec. 31, 2024 USD ($)	Dec. 31, 2017 USD ($)	May 31, 2017 USD ($)	Dec. 31, 2025 USD ($)	Dec. 31, 2024 USD ($)	Dec. 31, 2020 USD ($)	Dec. 31, 2020 USD ($)	Dec. 31, 2025 USD ($)	Dec. 31, 2025 USD ($) milestone
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenues					$ 39,552,000	$ 57,800,000
Revenue, performance obligation, termination Fee, consideration receivable		$ 5,000,000.0				5,000,000.0
Pfizer
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Agreement termination, term (in years)				15 years
Pfizer | License
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenues under agreement				$ 70,000,000.0
Potential amount to be funded for achievement of specified commercialized and sales milestones				$ 266,500,000
Collaborative arrangement, number of milestones achieved | milestone										2
Milestone payments received										$ 55,000,000.0
Revenues	$ 6,000,000.0					$ 0		$ 134,000,000.0
Revenue, performance obligation, termination fee, payable term (in days)						60 days
Revenue, performance obligation, termination fee, payable term if sublicense transfers (in days)		30 days
Pfizer | License | Certain Zinc Finger Nucleases (ZFN) Agreement
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenues					6,000,000.0
Pfizer | License | AAV Delivery System
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenues					5,000,000.0
Pfizer | License | Minimum
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Percentage of net sales per developed licensed product which will trigger royalties by counterparty (as a percent)				14.00%
Pfizer | License | Maximum
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Percentage of net sales per developed licensed product which will trigger royalties by counterparty (as a percent)				20.00%
Pfizer | License | Achievement of specified clinical development intellectual property and regulatory milestones
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Development and sales-based milestone payments to be received				$ 208,500,000
Alexion Pharmaceuticals, Inc., AstraZeneca Rare Disease
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Agreement termination, term (in years)			15 years
Milestone payments received			$ 12,000,000.0
Alexion Pharmaceuticals, Inc., AstraZeneca Rare Disease | License
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Milestone payments received									$ 5,000,000.0
Revenues					$ 0	$ 0	$ 17,000,000.0
Alexion Pharmaceuticals, Inc., AstraZeneca Rare Disease | License | Minimum
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Percentage of net sales per developed licensed product which will trigger royalties by counterparty (as a percent)			14.00%
Alexion Pharmaceuticals, Inc., AstraZeneca Rare Disease | License | Maximum
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Percentage of net sales per developed licensed product which will trigger royalties by counterparty (as a percent)			20.00%